Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (02196.HK) Latest Company News

Sep 18, 2026, 09:08 UTC
Shanghai Fosun Pharmaceutical (Group) repurchased 1.3 million of its own shares on September 18 at HK$17.35–17.58 per share for about HK$22.77 million, bringing cumulative buybacks to 9.759 million shares, or 1.8% of issued shares.
Source:
- aastocks.com
Sep 17, 2026, 07:06 UTC
Shanghai Fuzhenkang Biotechnology Co., Ltd. was established, jointly held by Fosun Pharma's wholly owned subsidiary Fosun Diagnostics Technology (Shanghai) Co., Ltd. and other shareholders.
Source:
- finance.sina.cn
Sep 16, 2026, 10:11 UTC
Fosun Pharma repurchased 1.3 million of its own shares on the Hong Kong Stock Exchange on September 16, 2026 at HK$16.91–17.26 per share for a total of HK$22.2439 million, to be held as treasury shares.
Source:
- finance.sina.cn
- aastocks.com
Sep 15, 2026, 09:56 UTC
Fosun Pharma repurchased 1.3 million of its own shares on the Hong Kong Stock Exchange on September 15, 2026 at HK$16.89–17.10 per share for a total of HK$22.0707 million, to be held as treasury shares.
Source:
Sep 8, 2026, 08:55 UTC
Fosun Pharma's controlling subsidiary received China's NMPA approval to conduct Phase II/III clinical trials for FXS5626 tablets to treat non-segmental vitiligo.
Source:
- finance.sina.cn
- aastocks.com
Sep 6, 2026, 08:55 UTC
Fosun Pharma's subsidiary will sell shares of Gland Pharma for approximately 294 million yuan.
Source:
Sep 4, 2026, 08:23 UTC
Fosun High Technology, the controlling shareholder of Fosun Pharma, pledged 330 million A-shares to ICBC Shanghai Changning Sub-branch on September 3, 2026, to secure debt repayment.
Source:
- finance.sina.cn
Sep 3, 2026, 10:01 UTC
China Medical System Holdings announced that its subsidiary Demei Pharmaceutical received approval from China's National Medical Products Administration for the new drug application of Opzelura (ruxolitinib cream) to add an indication for mild-to-moderate atopic dermatitis in China.
Source:
Sep 3, 2026, 09:44 UTC
Kanghong Pharmaceutical's wholly-owned subsidiary Chengdu Kanghong Biologics received regulatory approval from China's National Medical Products Administration to add a new indication for its Conbercept ophthalmic injection (brand name Lumitin), specifically for treating retinopathy of prematurity, marking the fifth approved indication for the drug.
Source:
- finance.sina.cn
Sep 3, 2026, 08:20 UTC
Fosun Pharma's controlled subsidiary received regulatory approval from China's National Medical Products Administration for a new indication of its drug Luwometinib (brand name Fumaining) for adult patients with symptomatic, inoperable plexiform neurofibromas in neurofibromatosis type I.
Source:
- finance.sina.cn
- aastocks.com
Aug 27, 2026, 11:56 UTC
Fosun Pharma announced that its subsidiary Yaoyu Pharmaceutical's licensed-in drug Weiketuo (GR1803), a BCMA×CD3 bispecific antibody, received conditional approval from China's National Medical Products Administration for treating relapsed or refractory multiple myeloma in adults who have received at least three prior lines of therapy.
Source:
- finance.sina.cn
- aastocks.com
Aug 25, 2026, 09:48 UTC
Fosun Pharma announced its first-half 2026 results: revenue of 20.442 billion yuan, up 4.75% year-on-year; net profit attributable to shareholders of 1.721 billion yuan, up 1.15% year-on-year.
Source:
- finance.sina.cn
- aastocks.com
Aug 21, 2026, 02:35 UTC
Fosun Pharma announced that the first participant in the China Phase I clinical trial of its liver-targeted siRNA drug FXR0906 for hypertriglyceridemia has been dosed.
Source:
- aastocks.com
Aug 18, 2026, 20:30 UTC
Chinese companies, including Fosun Pharma and Zhejiang Hisun Pharmaceutical, expressed interest in expanding partnerships with Jordan in pharmaceutical and food manufacturing, including joint ventures and R&D, during a meeting with King Abdullah in Shanghai.
Source:
- jordantimes.com
Aug 16, 2026, 23:48 UTC
Fosun Pharma's subsidiary Henlius signed a framework agreement with Sandoz AG for licensing cooperation on up to 10 biosimilar products, with initial terms for 3 products including payments up to $237 million.
Source:
Aug 13, 2026, 09:43 UTC
Fosun Pharma's controlled subsidiary initiated a Phase II clinical trial in China for FXS7553, a self-developed small-molecule oral DPP-1 inhibitor, to treat chronic obstructive pulmonary disease.
Source:
- aastocks.com
Aug 7, 2026, 11:38 UTC
Fosun Pharma's controlled subsidiary Fosun Pharma (Xuzhou) Co., Ltd. obtained registration approval from the National Medical Products Administration for its levalbuterol hydrochloride nebulized inhalation solution, with the approved indication being the treatment or prevention of related bronchospasm in adults and children over 6 years old.
Source:
- finance.sina.cn
Aug 7, 2026, 11:38 UTC
Fosun Pharma's controlling subsidiary Shanghai Zhaohui Pharmaceutical's dobutamine hydrochloride injection received registration approval from the National Medical Products Administration for treating heart failure.
Source:
- finance.sina.cn
- aastocks.com
Aug 3, 2026, 08:19 UTC
Fosun Pharma's controlled subsidiary Suzhou Erye Pharmaceutical received NMPA registration approval for its compound polyethylene glycol (3350) electrolyte powder, indicated for chronic constipation in children aged 1-11 and fecal impaction in children aged 5-11.
Source:
- finance.sina.cn
Aug 3, 2026, 08:19 UTC
Fosun Pharma's controlling subsidiary Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd. obtained registration approval from the National Medical Products Administration for Empagliflozin and Metformin Hydrochloride Extended-Release Tablets (III), indicated to improve glycemic control in adult patients with type 2 diabetes receiving empagliflozin and metformin hydrochloride treatment.
Source:
- finance.sina.cn
Jul 31, 2026, 08:34 UTC
Fosun Pharma's controlling subsidiary Henlius received approval from the National Medical Products Administration to conduct clinical trials of HLX43 injection combined with bevacizumab, with or without chemotherapy, for advanced/metastatic solid tumors.
Source:
Jul 24, 2026, 08:23 UTC
Fosun Pharma's subsidiary Fosun Wanbang received approval from the National Medical Products Administration to conduct a clinical trial for DM1001 to treat Parkinson's disease.
Source:
- finance.sina.cn
Jul 22, 2026, 08:23 UTC
Fosun Pharma's controlling shareholder Fosun High Technology released a pledge on 69 million A-shares on July 21, 2026, and disclosed a subsequent pledge plan.
Source:
- finance.sina.cn
Jul 10, 2026, 08:35 UTC
Fosun Pharma's subsidiary Henlius received NMPA approval to conduct a Phase I clinical trial of HLX37 combined with HLX43 for advanced/metastatic solid tumors.
Source:

02196.HK

Shanghai Fosun Pharmaceutical (Group) repurchased 1.3 million of its own shares on September 18 at HK$17.35–17.58 per share for about HK$22.77 million, bringing cumulative buybacks to 9.759 million shares, or 1.8% of issued shares.

Shanghai Fuzhenkang Biotechnology Co., Ltd. was established, jointly held by Fosun Pharma's wholly owned subsidiary Fosun Diagnostics Technology (Shanghai) Co., Ltd. and other shareholders.

Fosun Pharma repurchased 1.3 million of its own shares on the Hong Kong Stock Exchange on September 16, 2026 at HK$16.91–17.26 per share for a total of HK$22.2439 million, to be held as treasury shares.

Fosun Pharma repurchased 1.3 million of its own shares on the Hong Kong Stock Exchange on September 15, 2026 at HK$16.89–17.10 per share for a total of HK$22.0707 million, to be held as treasury shares.

Fosun Pharma's controlling subsidiary received China's NMPA approval to conduct Phase II/III clinical trials for FXS5626 tablets to treat non-segmental vitiligo.

Fosun Pharma's subsidiary will sell shares of Gland Pharma for approximately 294 million yuan.

Fosun High Technology, the controlling shareholder of Fosun Pharma, pledged 330 million A-shares to ICBC Shanghai Changning Sub-branch on September 3, 2026, to secure debt repayment.

China Medical System Holdings announced that its subsidiary Demei Pharmaceutical received approval from China's National Medical Products Administration for the new drug application of Opzelura (ruxolitinib cream) to add an indication for mild-to-moderate atopic dermatitis in China.

Fosun Pharma's controlled subsidiary received regulatory approval from China's National Medical Products Administration for a new indication of its drug Luwometinib (brand name Fumaining) for adult patients with symptomatic, inoperable plexiform neurofibromas in neurofibromatosis type I.

Fosun Pharma announced its first-half 2026 results: revenue of 20.442 billion yuan, up 4.75% year-on-year; net profit attributable to shareholders of 1.721 billion yuan, up 1.15% year-on-year.

Fosun Pharma announced that the first participant in the China Phase I clinical trial of its liver-targeted siRNA drug FXR0906 for hypertriglyceridemia has been dosed.

Chinese companies, including Fosun Pharma and Zhejiang Hisun Pharmaceutical, expressed interest in expanding partnerships with Jordan in pharmaceutical and food manufacturing, including joint ventures and R&D, during a meeting with King Abdullah in Shanghai.

Fosun Pharma's subsidiary Henlius signed a framework agreement with Sandoz AG for licensing cooperation on up to 10 biosimilar products, with initial terms for 3 products including payments up to $237 million.

Fosun Pharma's controlled subsidiary initiated a Phase II clinical trial in China for FXS7553, a self-developed small-molecule oral DPP-1 inhibitor, to treat chronic obstructive pulmonary disease.

Fosun Pharma's controlling subsidiary Shanghai Zhaohui Pharmaceutical's dobutamine hydrochloride injection received registration approval from the National Medical Products Administration for treating heart failure.

Fosun Pharma's controlled subsidiary Suzhou Erye Pharmaceutical received NMPA registration approval for its compound polyethylene glycol (3350) electrolyte powder, indicated for chronic constipation in children aged 1-11 and fecal impaction in children aged 5-11.

Fosun Pharma's controlling subsidiary Henlius received approval from the National Medical Products Administration to conduct clinical trials of HLX43 injection combined with bevacizumab, with or without chemotherapy, for advanced/metastatic solid tumors.

Fosun Pharma's subsidiary Fosun Wanbang received approval from the National Medical Products Administration to conduct a clinical trial for DM1001 to treat Parkinson's disease.

Fosun Pharma's controlling shareholder Fosun High Technology released a pledge on 69 million A-shares on July 21, 2026, and disclosed a subsequent pledge plan.

Fosun Pharma's subsidiary Henlius received NMPA approval to conduct a Phase I clinical trial of HLX37 combined with HLX43 for advanced/metastatic solid tumors.